Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. diarrhea
Show results for
Products
Services
Applications

Companies

News
Articles
Downloads
Videos

Refine by
Date

  • Older

Diarrhea Articles & Analysis

57 news found

Maynilad celebrates 2024 Global Handwashing Day in nine schools

Global Handwashing Day is an international advocacy that emphasizes the importance of washing hands with water and soap as a simple yet effective way to prevent illnesses such as diarrhea and pneumonia. Celebrated every October, GHD is observed in over 1 million schools across 100 countries, engaging more than 200 million people worldwide. ...

ByMaynilad Water Services, Inc.


Infection Control Resources to Protect Building Occupants from Norovirus and Other Pathogens

Infection Control Resources to Protect Building Occupants from Norovirus and Other Pathogens

According to the Centers for Disease Control and Prevention (CDC), it is the leading cause of vomiting and diarrhea, and foodborne illness in the United States. The agency also warns that infection with one type of norovirus may not protect an individual against other types. ...

ByCochrane & Associates, LLC


MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors

MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors

The most frequent treatment-emergent adverse events (AEs) determined to be possibly related to tulmimetostat included thrombocytopenia (47.1%), diarrhea (37.3%), nausea (29.4%), anemia (27.5%), fatigue (25.5%), neutropenia (17.6%), dysgeusia (17.6%), alopecia (15.7%) and vomiting (15.7%). ...

ByMorphoSys AG


MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022

MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022

The most common (≥25%) nonhematologic treatment-emergent AEs of any grade were diarrhea (43%), respiratory tract infection (41%), asthenic conditions (38%), musculoskeletal pain (32%), constipation (30%), nausea (29%), dizziness (27%) and abdominal pain (26%). ...

ByMorphoSys AG


Lumen Bioscience Awarded $3.6 Million by U.S. Army to Advance Low-cost, Scalable Preventative for Antibiotic-Resistant Infections

Lumen Bioscience Awarded $3.6 Million by U.S. Army to Advance Low-cost, Scalable Preventative for Antibiotic-Resistant Infections

Lumen's clinical pipeline includes investigational biologic drugs for C. difficile infection, Covid-19, cardiometabolic disease, inflammatory bowel disease, norovirus, and traveler's diarrhea. ...

ByLumen Bioscience, Inc.


Sage Therapeutics and Biogen Present Further Analyses from Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression at the European College of Neuropsychopharmacology (ECNP) Congress

Sage Therapeutics and Biogen Present Further Analyses from Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression at the European College of Neuropsychopharmacology (ECNP) Congress

Common TEAEs (>5% in the zuranolone 50 mg arm) were somnolence, dizziness, sedation, headache, diarrhea, nausea, urinary tract infection and COVID-19. Sage Therapeutics and Biogen have initiated a rolling submission of a New Drug Application (NDA) to the U.S. ...

BySage Therapeutics


FDA Approves Taiho’s LYTGOBIĀ® (futibatinib) Tablets for Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma

FDA Approves Taiho’s LYTGOBIĀ® (futibatinib) Tablets for Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma

The most common (≥20%) adverse reactions were nail toxicity, musculoskeletal pain, constipation, diarrhea, fatigue, dry mouth, alopecia, stomatitis, dry skin, arthralgia, dysgeusia, abdominal pain, dry eye, nausea, decreased appetite, urinary tract infection, palmar-plantar erythrodysesthesia syndrome, and vomiting. ...

ByTaiho Oncology, Inc.


Blood ties: The inspiration behind a potential sepsis breakthrough

Blood ties: The inspiration behind a potential sepsis breakthrough

His entire body became inflamed and swollen, his skin stretched so tightly that his blood was visible beneath his skin, like magma bubbling at a crack in the Earth’s surface. He suffered severe diarrhea and multiple heart attacks until, one by one, his organs began to shut down. ...

BySepset Biosciences Inc.


Taiho Oncology Announces Updated Efficacy and Safety Data for Futibatinib in Cholangiocarcinoma at 2022 ASCO Annual Meeting

Taiho Oncology Announces Updated Efficacy and Safety Data for Futibatinib in Cholangiocarcinoma at 2022 ASCO Annual Meeting

The most common treatment-related adverse events (TRAEs) were hyperphosphatemia (85%), alopecia (33%), dry mouth (30%), diarrhea (28%), dry skin (27%) and fatigue (25%). Most TRAEs were of mild or moderate intensity and manageable. ...

ByTaiho Oncology, Inc.


Onconova Therapeutics Announces Abstract At The ASCO Annual Meeting Highlighting Narazaciclib’s Differentiated Inhibitory And Improved Safety Profile In Preclinical Models

Onconova Therapeutics Announces Abstract At The ASCO Annual Meeting Highlighting Narazaciclib’s Differentiated Inhibitory And Improved Safety Profile In Preclinical Models

Narazaciclib’s inhibitory activity against GSK3β, a kinase whose inhibition putatively causes tolerability issues related to diarrhea, is ~29 times less than that of abemaciclib. Cellular kinase assays showed narazaciclib’s highest inhibitory activity to be against CDK4/6, CSF1R, (supports pro-tumor immune suppression), and NUAK1/ARK 5 (associated with poor ...

ByTraws Pharma


The Essential Guide to Food Allergies

The Essential Guide to Food Allergies

Digestive symptoms further include bouts of nausea and vomiting. Abdominal pain and episodic diarrhea may also be observed. Swelling of lips, tongue, and other parts of the body, and eczema, rashes and hives are very common signs of developing an allergy. ...

ByHYCOR Biomedical


Fecal biomarkers - diagnostic possibilities in the context of inflammatory bowel disease

Fecal biomarkers - diagnostic possibilities in the context of inflammatory bowel disease

During relapses, acute inflammation occurs in the bowel of IBD patients, leading to typical symptoms such as chronic diarrhea, abdominal pain, and/or weight loss. However, these symptoms are not specific to IBD, but can also be caused, for example, by irritable bowel syndrome (IBS). ...

ByImmundiagnostik AG


Amgen And Lance Bass Partner To Encourage People To Do A `Double Take` To Recognize The Early Signs Of Psoriatic Arthritis

Amgen And Lance Bass Partner To Encourage People To Do A `Double Take` To Recognize The Early Signs Of Psoriatic Arthritis

THOUSAND OAKS, Calif., May 12, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Otezla® (apremilast) have partnered with pop icon and entrepreneur Lance Bass, for the Double Take campaign to empower people to take action when it comes to psoriatic arthritis. As a singer, dancer and entertainer, Bass understands the importance of staying in tune with your body. Through the campaign, he has created ...

ByAmgen Inc.


Amgen And Lance Bass Partner To Encourage People To Do A `Double Take` To Recognize The Early Signs Of Psoriatic Arthritis

Amgen And Lance Bass Partner To Encourage People To Do A `Double Take` To Recognize The Early Signs Of Psoriatic Arthritis

The most common side effects reported in more than 5% of patients are diarrhea, nausea, and headache. To learn more about Bass' story, the Double Take dance, and the signs and symptoms of psoriatic arthritis, visit ...

ByAmgen Inc.


Blue Earth Diagnostics Announces Key Results from Phase 3 SPOTLIGHT Study of iaF-rhPSMA-7.3, an Investigational PET Imaging Agent, in Biochemical Recurrence of Prostate Cancer

Blue Earth Diagnostics Announces Key Results from Phase 3 SPOTLIGHT Study of iaF-rhPSMA-7.3, an Investigational PET Imaging Agent, in Biochemical Recurrence of Prostate Cancer

The most frequently reported events were: hypertension: 1 (n=7); diarrhea: 1.0% (n=4); injection site reaction: 0.5% (n=2), and headache: 0.5% (n=2). ...

ByBlue Earth Diagnostics


Lupin Signs Promotional Agreement with Exeltis on SOLOSECĀ® expanding access for Adult Women Suffering with Bacterial Vaginosis and Adults with Trichomoniasis

Lupin Signs Promotional Agreement with Exeltis on SOLOSECĀ® expanding access for Adult Women Suffering with Bacterial Vaginosis and Adults with Trichomoniasis

Most common adverse reactions observed in clinical trials (incidence ≥2%) were vulvovaginal candidiasis, headache, nausea, dysgeusia, vomiting, diarrhea, abdominal pain, and vulvovaginal pruritus. To report SUSPECTED ADVERSE REACTIONS, contact Lupin Pharmaceuticals, Inc. at 1-844-SOLOSEC (1-844-765-6732) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. ...

ByLupin Limited


AVEO Oncology Presents Three Posters for Tivozanib/Immunotherapy Combinations at the 2022 ASCO GI Cancers Symposium

AVEO Oncology Presents Three Posters for Tivozanib/Immunotherapy Combinations at the 2022 ASCO GI Cancers Symposium

ADVERSE REACTIONS The most common (≥20%) adverse reactions were fatigue, hypertension, diarrhea, decreased appetite, nausea, dysphonia, hypothyroidism, cough, and stomatitis, and the most common Grade 3 or 4 laboratory abnormalities (≥5%) were sodium decreased, lipase increased, and phosphate decreased. ...

ByAVEO Pharmaceuticals, Inc.


Fractyl Health Provides Initial Clinical Update on Open-Label REVITA-T2Di

Fractyl Health Provides Initial Clinical Update on Open-Label REVITA-T2Di

In the nine treated subjects, there have been no device- or procedure-related Serious Adverse Events (SAEs) and no AESI (such as nausea, vomiting, or diarrhea, as defined in conjunction with the FDA). One subject who did not tolerate empagliflozin therapy withdrew from the study for reasons that were not related to Revita. ...

ByFractyl Health


Cara Therapeutics Announces Difelikefalin (KORSUVA) Injection Achieves Positive Topline Results in Phase 3 Clinical Study in Japan for the Treatment of Pruritus in Hemodialysis Patients

Cara Therapeutics Announces Difelikefalin (KORSUVA) Injection Achieves Positive Topline Results in Phase 3 Clinical Study in Japan for the Treatment of Pruritus in Hemodialysis Patients

Adverse Reactions The most common adverse reactions (incidence ≥2% and ≥1% higher than placebo) were diarrhea (9.0%), dizziness (6.8%), nausea (6.6%), gait disturbances, including falls (6.6%), hyperkalemia (4.7%), headache (4.5%), somnolence (4.2%), and mental status changes (3.3%). ...

ByCara Therapeutics.


AVEO Oncology Highlights Recent Progress and 2022 Outlook

AVEO Oncology Highlights Recent Progress and 2022 Outlook

ADVERSE REACTIONS The most common (≥20%) adverse reactions were fatigue, hypertension, diarrhea, decreased appetite, nausea, dysphonia, hypothyroidism, cough, and stomatitis, and the most common Grade 3 or 4 laboratory abnormalities (≥5%) were sodium decreased, lipase increased, and phosphate decreased. ...

ByAVEO Pharmaceuticals, Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT